A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate-9KD) identifier:
NCT03338790 (


Study Contact Information:

Individuals interested in enrolling should contact the person listed as the contact for each study site. If no contact is listed, they should reach out to [email protected]

About the Study

CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. The purpose of this study is to compare three different combination therapies, each containing a drug called nivolumab and another anti-cancer drug. All three combination therapies are considered investigational, which means that they are not currently approved to treat men with metastatic prostate cancer.  The three drugs which will be studied in combination with Nivolumab are:

The study doctors want to learn more about which combination therapy is most effective in treating metastatic prostate cancer.

Visit Bristol-Myers Squibb's Study Connect site or for more information on the study. 

NOTE: This study is no longer enrolling. 


Type of Study

CheckMate-9KD is a three-arm, non-randomized, open-label study.

What the Study Entails

Biopsy sample. All patients interested in enrolling must submit pre-treatment tumor tissue. Participants with tissue from a prior biopsy acquired within 5 years of enrollment will not require additional biopsy. Participants who do not have available tissue from a prior biopsy must undergo a biopsy in order to participate.

Treatment arms. All participants will be assigned to one of three treatment groups.

Treatment arm assignment. Treatment arm assignment will depend on the following variables:

Monitoring and follow up visits.


This Study is Open To:

NOTE: This study is no longer enrolling. 

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.